Introduction
============

Model physiological systems that integrate different human cell types, while maintaining normal physiological responses and month-long cell viability in defined, serum-free media, are needed to facilitate the replacement of animals in preclinical drug screens with *in vitro*platforms. Our team\'s philosophy is to keep these systems as simple as possible to hold down cost and only add complexity to enable increased functionality, if needed for better evaluation capabilities. Design of our systems is guided by a computer model of the body (a physiologically based pharmacokinetic (PBPK) pharmacodynamic model), referred to as a micro-cell culture analog (μCCA) or a \'Body-on-a-Chip\'. In an article entitled \'Tissue Models: A Living System on a Chip\' \[[@B1]\], Shuler\'s group is credited with conceiving of this approach, and with demonstrating its broad feasibility. Our *in vitro*system, unlike other *in vitro*methods, provides realistic dose dynamics and allows for metabolite exchange between compartments. Furthermore, the natural length scale of the model (10 to 100 μm) is consistent with physiological length scales.

Hickman\'s group has developed a defined base media system that enables culture of a wide range of cell types for many months, and removes a major variable (serum) from the system. Hickman\'s group published the first serum-free, defined culture system for neurons in 1995 \[[@B2]\] and has since then advanced this work from the use of rodent cells to human cells. In most cases, the cultured cells have been shown to maintain functionality for at least 2 to 3 months in this system. This common, defined media system utilization has been expanded to include human neurons \[[@B3],[@B4]\], glia \[[@B5],[@B6]\], muscle \[[@B3]\] and cardiomyocytes \[[@B7]\] from adult, fetal and embryonic stem cell sources. Hickman\'s group has progressed in the creation of a functional neuromuscular junction model for rat-rat \[[@B8]\] to rat-human \[[@B4]\] to human-human \[[@B3]\] using the same basic serum-free culture system.

Owing to space constraints, a complete overview of the design and validation of all current \'Body-on-a-Chip\' technologies is beyond the scope of this article. For a more complete assessment of the field, refer to the reviews in \[[@B9],[@B10]\] and references cited therein. This paper will instead highlight the advances our group has made in developing a multiorgan \'Body-on-a-Chip\' platform, as well as our achievements in developing functional assays of a variety of tissues for eventual integration into this model.

Design and validation of a multiorgan *in vitro*system
======================================================

The fabrication of a microfluidic device that used living cell tissue constructs, interconnected as they are in the body, was conceived by Shuler, Baxter and others (US Patent \#7,288,405 2007). The concept for a \'Body-on-a-Chip\' microphysiological system comes from the desire to emulate a PBPK pharmacodynamic mathematical model using a physical model. By combining PBPK pharmacodynamic models with the experimental device, the quality of predictions and depth of understanding can be increased \[[@B11],[@B12]\]. Shuler\'s group has demonstrated such a device and its use in emulating key aspects of the human response to combination treatment of colon cancer, using tegafur and uracil \[[@B12]\].

This effort is currently being expanded by exploring designs of devices with up to 13 tissue compartments. Figure [1](#F1){ref-type="fig"} shows the design of a 10-compartment system currently in development. Measurements can be made using microscopy, integrated microelectrode arrays, bio-microelectromechanical system (BioMEMS) devices and using conditioned medium samples sent to microanalytical systems. Initial tests demonstrate that this system can maintain high cell viability (85 to 95%) in all compartments using HepG2-C3A cells, over a 48-hour period, without medium replacement. The fluid flow to each compartment is consistent with design values, and the overall blood surrogate recirculation time (approximately 6 minutes) is consistent with the expected physiological value.

![**Overview of a 10-chamber in vitro model**. Overview of our 10-chamber *in vitro*model based on a simplified three-chamber system using gravity-driven flow \[[@B12]\]. **(A)**Prototype unit on a rocker platform. **(B)**Close-up inverted view of the prototype unit after a dye distribution study. **(C)**Exploded schematic showing the compartmentalization design for a 10-chamber system within this single unit. Barrier tissues (for example, gastrointestinal (GI) tract, skin, and so forth) are made by plating cells and allowing them to grow into a layer on a pretreated polycarbonate membrane (0.4 μm pore size) that was sandwiched between a chamber gasket and another gasket or a polycarbonate channel plate creating chambers for the cells. The design provides an apical and a basolateral side for each chamber, allowing passage of chemicals across the barrier. Nonbarrier tissues are three-dimensional constructs made by resuspending cells in hydrogels or plating them on a polymeric scaffold. The three-dimensional tissue constructs are placed directly onto a polycarbonate membrane that is again sandwiched between a chamber gasket and another gasket or polycarbonate channel plate creating the chambers for the cells.](scrt370-1){#F1}

Cardiac model
=============

The Hickman group has developed an *in vitro*method for pharmacological cardiac side-effect testing, which uses surface-modified commercially available multi-electrode arrays (MEAs). The surface of the multi-electrode array is patterned with a cytophobic polyethylene-glycol selfassembled monolayer, and the cytophilic biopolymer fibronectin \[[@B7]\]. Rat cardiac myocytes plated onto patterned multi-electrode arrays are stable in culture for at least 60 days, and have been used to test functional responses to two drugs: 1-heptanol, a gap junction blocker; and sparfloxacin, a fluoroquinone antibiotic. Integration of these systems with BioMEMS cantilever devices also allows for direct force measurement to be made.

Central/peripheral nervous system and skeletal muscle models
============================================================

The culture parameters for the long-term maintenance and maturation of both embryonic and adult rat hippocampal neurons in serum-free conditions have been established by the Hickman group \[[@B13]\]. Such cells are amenable to interrogation with patch clamp electrodes \[[@B13]\] and multi-electrode arrays \[[@B14]\], and display mature morphology as well as electrical function.

We have published extensively on the establishment of motoneuron \[[@B15],[@B16]\] and muscle \[[@B17]\] cultures, utilizing cells from both human stem cell \[[@B3],[@B4],[@B15]\] and rodent \[[@B16],[@B18]\] sources. Furthermore, our group has detailed the development of human stem-cell-derived co-cultures for analysis of neuromuscular junction formation *in vitro*\[[@B3]\]. Human motoneuron-muscle co-cultures, cultured using our protocols, have been shown to survive for 30+ days *in vitro*and to form synaptic connections responsive to stimulation with excitatory neurotransmitters (for example, glutamate) and to be inhibited through treatment with acetylcholine receptor antagonists (for example, Dtubocurarine) \[[@B3]\]. Muscle-only systems have been integrated with BioMEMS cantilever chips to allow direct force readouts of muscle function \[[@B17],[@B19],[@B20]\].

The Hickman laboratory has also demonstrated the capacity to maintain co-cultures of rat intrafusal muscle fibers with sensory neurons \[[@B21]\]. Recently, we published the first *in vitro*culture model capable of differentiating and maintaining human, stem-cell-derived sensory neurons displaying full electrical functionality \[[@B22]\]. We are currently working on developing a model capable of replicating all aspects of the reflex arc with human cells *in vitro*\[[@B23]\].

Lung model
==========

The Hickman and Shuler groups have developed a microfluidic device that reproduces the microenvironment of the lung alveoli, to produce controlled gas concentrations in both the gas and liquid sides of the alveolus-capillary interface, and to measure changes in functional gas transfer through the epithelial-endothelial bilayer \[[@B24]\]. The alveolar microfluidic device contains a number of chambers for microenvironment maintenance and monitoring. The primary chamber was designed to contain the cellular alveolus-capillary interface construct. An upstream conditioning chamber was incorporated to control the dissolved gas concentrations in the incoming liquid, acting as a blood analog, and downstream chambers were included to house dissolved gas sensors for monitoring output concentrations. This silicon-based device allows the control and maintenance of gas concentrations in both gas and liquid chambers. Changes to the health of the alveoli can be monitored under various conditions including restricted lung capacity, altered blood compositions, and disease states involving the alveolar-capillary interface.

Gastrointestinal tract/liver model
==================================

Absorbed drugs that have crossed the gastrointestinal tract mucosa and epithelium are transported directly to the liver via the portal vein. \'Body-on-a-Chip\' constructs, that contain both the gastrointestinal tract and the liver, can therefore simulate the uptake and first-pass metabolism of drugs. The detection of metabolites of acetaminophen within such a system has recently confirmed that this is possible with a two-organ *in vitro*model by Shuler and colleagues \[[@B25]\].

Shuler\'s group and others have expanded simple Caco-2 cell culture models to two-cell-type and three-cell-type cultures that consist of Caco-2 cells, mucusproducing HT-29 cells, and M-cells \[[@B26],[@B27]\]. Using this system Shuler and colleagues have recently simulated the oral uptake of 50 and 200 nm polystyrene particles, and have found that M-cells are needed to simulate the uptake of the larger particles \[[@B27]\]. The group has also developed microfluidic models that contained this three-cell-type gastrointestinal tract tissue and simulated the uptake of acetaminophen and its subsequent actions in the liver \[[@B25]\]. PBPK simulations of these devices indicated that after 24 hours the acetaminophen dose in the device was \~90% of that expected in humans after 24 hours. They have begun to culture Caco-2 cells on three-dimensional surfaces that allow the cells to form macro-villi, thereby enabling drug transport studies across a three-dimensional tissue interface \[[@B28],[@B29]\].

Sung and Shuler have developed a micro-device that uses Matrigel and confers a three-dimensional environment which facilitates the expression of CYP450 enzymes by cultured hepatocytes \[[@B30]\]. The current work concentrates on the integration of primary hepatocytes with non-parenchymal cells, cultivated in a three-dimensional scaffold \[[@B31]\], to better mimic the physiological situation. Initial experiments using non-parenchymal cells and a HepG2/C3A liver model, cultivated in our gravity-driven flow device, have shown sustained biological activity for 28 days *in vitro*, including inducible CYP450 activity (CYP1A1 and CYP3A4) and albumin synthesis.

Barrier tissues model
=====================

Shuler\'s approach to modeling the blood-brain barrier is to utilize microfabricated membranes, which are manufactured as integral parts of microfluidic chambers \[[@B28],[@B32]\], to culture brain endothelial cells and astrocytes within microfluidic chambers. These will enable the testing of hypotheses related to the need for physical contact between endothelial cells and astrocytes. Recent work by Lippmann and colleagues \[[@B33]\] and by Shayan and colleagues \[[@B34]\] has shown that brain endothelial cells respond to the presence of astrocytes in culture, acquiring substantial barrier properties, as indicated by high transendothelial electrical resistance measurements.

Shuler\'s work in developing an *in vitro*model of the capillary network has focused on characterizing endothelial cell (human umbilical vein endothelial cell) growth in small microfluidic vessels (50 μm × 50 μm). In vessels of this size, the sidewalls become significant surfaces. Characterization with confocal microscopy has shown that human umbilical vein endothelial cells grown in small microfluidic channels exhibit barrier function (as indicated by immunostained vascular endothelial cadherin) throughout the vessels and even on the sidewalls when the cells are cultured under sufficient shear stress \[[@B35]\].

Fat model
=========

Since \'Body-on-a-Chip\' models must include the complete set of organs either implicitly or explicitly, the fat compartment is often included implicitly. However, modeling the fat compartment explicitly may have advantages. In experiments with environmental toxins (naphthalene) Shuler has found that the presence of a fat compartment, represented by differentiated 3T3-L1 adipocytes, modulates the response of the system (in particular, lung cells) to the toxin. Adipocytes presumably ameliorate damage to co-cultured cells through absorption of toxins and damaging compounds, such as hydrogen peroxide, and prevention of glutathione depletion \[[@B36]\].

Conclusions
===========

Our groups have focused on developing increasingly authentic functional tissue constructs to incorporate into a multi-tissue platform based on a PBPK model. While there are significant challenges in constructing an integrated 10-organ, all-human system, the advances so far made by our team lead us to believe we have a good basis to construct a functional human model. Issues such as availability, cost, and ability to display adult cell physiology and phenotype will soon be solved, to allow greater incorporation of stem cells into these modules and ultimately more authentic tissue constructs and improved modules in this microphysiological system.

Abbreviations
=============

BioMEMS: bio-microelectromechanical system; PBPK: physiologically based pharmacokinetic.

Competing interests
===================

HuRel has licensed Cornell patents (for example, US Patent 5,728,580 (1998) and US Patent 7,288,405 (2007)) that underlie the \'Body-on-a-Chip\' concept. MLS is on the scientific advisory board for HuRel.

Acknowledgements
================

This research was funded by National Institutes of Health grant numbers 1UH2TR000516-01, R01NS050452 and R01EB005459. The publication costs for this article were funded by National Institutes of Health grant number UH2TR000516.

Declarations
============

Publication of this supplement has not been supported by sponsorship. Articles have undergone the journal\'s standard review process. The Editors declare that they have no competing interests.

This article has been published as part of *Stem Cell Research & Therapy*Volume 4 Supplement 1, 2013: Stem cells on bioengineered microphysiological platforms for disease modeling and drug testing. The full contents of the supplement are available online at <http://www.stemcellres.com/supplements/4/S1>.
